You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 6,143,326


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,143,326
Title: Oral pharmaceutical preparation containing ibandronat
Abstract:The invention is directed to well-tolerated pharmaceutical compositions for oral application, containing ibandronate or a physiologically tolerable salt thereof as active substance, the administration form consisting of an active substance-containing inner portion enclosed in such fashion by a coat free of active substance that rapid release of the active substance takes place.
Inventor(s): Mockel; Jorn (Heidelberg, DE), Gabel; Rolf-Dieter (Schwetzingen, DE), Woog; Heinrich (Laudenbach, DE)
Assignee: Roche Diagnostics GmbH (Mannheim, DE)
Application Number:09/147,149
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Dosage form;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 6,143,326

Introduction

Patent 6,143,326, like many other patents, is a complex document that outlines specific inventions and their claims. To analyze this patent, we need to delve into its background, the technology it covers, the claims made, and how it fits into the broader patent landscape.

Background of the Patent

To begin with, it is essential to understand the context in which the patent was filed and granted. The U.S. Patent and Trademark Office (USPTO) is responsible for granting patents, and each patent must meet specific criteria to be approved[2].

Patent Details

  • Patent Number: 6,143,326
  • Grant Date: This information is not provided in the sources, but it can be found through the USPTO database.
  • Inventor(s) and Assignee: The inventors and the assignee of the patent are crucial for understanding the ownership and the development process of the invention.
  • Technology Area: Patents are classified into various technology areas based on the World Intellectual Property Organization (WIPO) classification. This helps in understanding the broader technological field the patent belongs to[4].

Claims Analysis

The claims section of a patent is the most critical part as it defines the scope of the invention.

Types of Claims

  • Independent Claims: These claims stand alone and define the invention without reference to other claims.
  • Dependent Claims: These claims refer back to and further limit the independent claims.

Claim Structure

Each claim is carefully crafted to ensure it is novel, non-obvious, and useful. The structure typically includes:

  • Preamble: Introduces the subject matter of the claim.
  • Transition Phrase: Connects the preamble to the body of the claim (e.g., "comprising," "consisting of").
  • Body of the Claim: Describes the elements and limitations of the invention[3].

Patent Scope

The scope of a patent is determined by its claims. Here are some key aspects to consider:

Novelty and Non-Obviousness

The invention must be novel and non-obvious over the prior art. This means it must be new and not an obvious variation of existing technology.

Usefulness

The invention must have a practical application or be capable of being used in some way.

Enablement

The patent must provide enough detail so that a person of ordinary skill in the relevant field can make and use the invention.

Patent Landscape

Understanding the patent landscape involves looking at related patents and how they interact.

Related Patents

  • Continuations and Continuations-in-Part: These are subsequent patent applications that claim priority from an earlier application. For example, the Cellect patents were continuations-in-part of earlier patents, each claiming priority from a single application[1].
  • Patent Families: These are groups of patents that are related through priority claims. Each member of the family may have different claims but shares a common ancestry.

Technology Trends

Analyzing trends in patent filings can provide insights into the direction of innovation in a particular field. For instance, electrical and mechanical engineering patents have seen significant growth, with electrical engineering patents more than doubling between 2000 and 2018[4].

Legal and Regulatory Considerations

Patents are subject to various legal and regulatory requirements.

Obviousness-Type Double Patenting (ODP)

This is a doctrine that prevents the same inventor from obtaining multiple patents for the same invention. The USPTO must perform an ODP analysis to ensure that patents do not overlap in their claims[1].

Patent Term Adjustment (PTA)

This is a provision that adjusts the term of a patent based on delays during the prosecution process. Each patent in a family may receive a different PTA, affecting their expiration dates[1].

Case Studies and Precedents

Court decisions and appeals can provide valuable insights into how patents are interpreted and enforced.

Restriction Requirements

The USPTO can issue restriction requirements if an application contains multiple independent and distinct inventions. This was seen in the case of Hyatt v. USPTO, where the applicant's amended claims were subject to a restriction requirement due to changes in the invention[5].

Key Takeaways

  • Claims are Critical: The claims section of a patent defines its scope and is the most important part of the patent.
  • Novelty and Non-Obviousness: The invention must be new and not an obvious variation of existing technology.
  • Patent Families: Understanding related patents and their priority claims is essential for navigating the patent landscape.
  • Legal Considerations: ODP analysis and PTA are crucial for ensuring the validity and term of a patent.

FAQs

  1. What is the purpose of the claims section in a patent?

    • The claims section defines the scope of the invention and is the most critical part of the patent.
  2. How does the USPTO classify patents technologically?

    • The USPTO uses the World Intellectual Property Organization (WIPO) classification, which includes 35 International Patent Classification (IPC) technical fields[4].
  3. What is Obviousness-Type Double Patenting (ODP)?

    • ODP is a doctrine that prevents the same inventor from obtaining multiple patents for the same invention[1].
  4. What is Patent Term Adjustment (PTA)?

    • PTA adjusts the term of a patent based on delays during the prosecution process[1].
  5. Why are restriction requirements issued by the USPTO?

    • Restriction requirements are issued when an application contains multiple independent and distinct inventions, requiring the applicant to select which claims to pursue in the initial examination[5].

Sources

  1. In re Cellect - United States Court of Appeals for the Federal Circuit
  2. U.S. Patent and Trademark Office (USPTO) | USAGov
  3. Patent and patent application Claims data (Stata (.dta) and MS Excel ...
  4. Invention: U.S. and Comparative Global Trends
  5. Hyatt v. United States Patent and Trademark Office

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 6,143,326

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,143,326

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany196 15 812Apr 20, 1996
PCT Information
PCT FiledApril 21, 1997PCT Application Number:PCT/EP97/01940
PCT Publication Date:October 30, 1997PCT Publication Number: WO97/39755

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.